Status:
COMPLETED
Immunological Response of Bladder Cancer Patients Under BCG
Lead Sponsor:
University of Campinas, Brazil
Collaborating Sponsors:
Coordination for the Improvement of Higher Education Personnel
Pontifical University Catholic of Campinas
Conditions:
Bladder Cancer
Bacillus Calmette-Guerin
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Bladder cancer (BC) is one of the most common cancers worldwide and the most successful example of vaccine in cancer treatment, representing an efficient model for studying the importance of systemic ...
Detailed Description
Recognizing patient-to-patient variability, key data scarcity, and insight into traditional reductionist therapy, the BCG model offers exceptionally compelling opportunities to understand how immune s...
Eligibility Criteria
Inclusion
- NMIBC with the indication for intravesical BCG treatment;
Exclusion
- Previous BCG treatment;
- Muscle invasive tumor.
Key Trial Info
Start Date :
September 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 18 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04806178
Start Date
September 3 2021
End Date
August 18 2024
Last Update
December 9 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pontifical Catholic University of Campinas Hospital
Campinas, São Paulo, Brazil, 13034685
2
Hospital das Clínicas Unicamp
Campinas, São Paulo, Brazil, 13083887